Highlights Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Delayed Nasdaq Other stock markets 17:42:23 23/05/2024 BST			5-day change	1st Jan Change
1.11 ^USD	-3.48%		-16.54%	+174.21%

05-10	Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-25	Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Nexalin Technology Files $5.6 Million Shelf Registration	04-16	MT
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	04-09	CI
Top Midday Gainers	03-28	MT
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	03-28	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman	03-14	CI
Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia	03-06	CI
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device	02-08	CI
Nexalin Technology, Inc. Unveils Gen-3 HALO?? Clarity 15 Milliamp Neurostimulation Device	01-11	CI
Nexalin Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal	16/10/23	CI
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms	07/08/23	CI
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's TACS Devices in the Asia Pacific Region	01/06/23	CI
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23	CI
NEXALIN TECHNOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	27/03/23	AQ
Nexalin Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Highlights

Filters